TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol

Ítems similars

• Patient stratification for determining optimal second and third line therapy for type 2 diabetes: the TriMaster study
  per: Shields, Beverley M, et al.
  Publicat: (2023)
• Patient preference for second and third line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study
  per: Shields, Beverley M, et al.
  Publicat: (2023)
• Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes
  per: Bailey, Clifford J., et al.
  Publicat: (2019)
• Sex and BMI alter the benefits and risks of sulfonylureas and thiazolidinediones in type 2 diabetes: A framework for evaluating stratification using routine clinical and individual trial data
  per: Dennis, John M, et al.
  Publicat: (2018)
• The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
  per: Schernthaner, Guntram, et al.
  Publicat: (2014)